A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

NCT ID: NCT06886139

Last Updated: 2025-08-22

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 139 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2027-09-30

Brief Summary

This trial is a multicenter, open-label, single-arm, Phase II Study. Patients with CD20 positive recurrent or refractory diffuse large B-cell lymphoma and had failed ≥2 prior lines of standard treatment will be recruited. The purpose of this trial is to evaluate the efficacy, safety, pharmacokinetic (PK) and immunogenicity characteristics of TRS005 via intravenous drip.

Detailed Description

The participants were screened and examined according to the protocol before enrollment. Participants received TRS005 at a dose of 1.8 mg/kg intravenously on day 1 of each 21-day cycle. The primary endpoints were objective response rate (ORR) assessed by Independent Review Committee (IRC). Participants were assessed for efficacy at the end of cycle 2, cycle 4, cycle 6 and every 4 subsequent cycles (each cycle is 21 days). Tumor responses were assessed by computerized tomography (CT) or positron emission tomography-computerized tomography (PET-CT) scanning per the Lugano 2014 criteria. The safety were assessed per the National Cancer Institute-Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

Conditions

CD20-positive Diffuse Large B-Cell Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TRS005

Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection (TRS005). TRS005 at a dose of 1.8 mg/kg intravenously on day 1 of each 21-day cycle.

Group Type: EXPERIMENTAL

TRS005

Intervention Type: DRUG

Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection. To be used under medical supervision.

Interventions

TRS005

Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection. To be used under medical supervision.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ≥ 18 years, gender is not limited.

2. The participants need to undergo pathological biopsy of tumor tissue.. Confirmed by histopathology with CD20-positive DLBCL, except for High-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-DH), and histologic transformed DLBCL according to the WHO 2022 revised classification standards.

3. Relapse or refractory after at least 2 lines of sufficient standard treatment regimens.

4. Not considered to be eligible for Autologous Stem Cell Transplant (ASCT).

5. Have measurable disease, including at least 1 nodal site measuring >1.5 cm or 1 extranodal site measuring >1.0 cm in longest dimension on computed tomography (CT).

6. Previously received anti-tumor treatment such as radiotherapy, biotherapy, immunotherapy at least 28 days before the first administration of this study; chemotherapy at least 21 days before the first administration of this study; hormone therapy at least 14 days before the first administration of this study.

7. Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 (CTCAE 5.0) to prior anti-cancer therapy.

8. Organ Function Requirements：Adequate hematologic, renal, and hepatic function.

9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

10. Participants must have a life expectancy of ≥3 months.

11. For women of childbearing potential and men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception. For women of childbearing potential, a negative serum pregnancy test result within 7 days before the first administration.

12. All participants and/or their parents or legal guardians must sign a written informed consent form.

Exclusion Criteria

1. A history of drug allergy to components of the test drug, xenoproteins, biological agents, etc., or severe infusion reaction after previous monoclonal antibody treatment.

2. Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load; Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load; Human immunodeficiency virus (HIV) seropositive.

3. Tumor-infiltrating diseases of the central nervous system.

4. Prior systemic treatment of lymphoma with MMAE-containing ADC drugs.

5. Prior treated with radiotherapy covering more than 30% of the bone marrow area.

6. ≥Grade 2 or greater baseline peripheral neuropathy.

7. Investigator-assessed diabetes uncontrolled by drug therapy.

8. Participants with other malignancies within the past 5 years.

9. Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath, etc.).

10. Active of autoimmune disease or immune deficiency.

11. Accompanied significant cardiovascular disease.

12. Participants who received autologous stem cell transplantation and CAR-T within 3 months prior to first administration; Participants who have received allogeneic stem cell transplantation in the past.

13. Participants must not have an uncontrolled infection.

14. Various vaccines were inoculated within 28 days prior to first administration.

15. Participate in clinical trials of other drugs or medical devices within 28 days prior to first administration.

16. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

17. Pregnancy and/or active Breast Feeding.

18. Investigators assessed as unsuitable to participate in this study for other reasons.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhejiang Teruisi Pharmaceutical Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yuankai Shi, MD

Role: PRINCIPAL_INVESTIGATOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Locations

Chinese Academy of Medical Sciences, Cancer Hospital

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Chen Wang

Role: CONTACT

chen.wang@teruisipharm.com

(+86)18832374527

Other Identifiers

TRS00502001

Identifier Type: -

Identifier Source: org_study_id